These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22474378)

  • 1. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.
    Santi DV; Schneider EL; Reid R; Robinson L; Ashley GW
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6211-6. PubMed ID: 22474378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrogel drug delivery system with predictable and tunable drug release and degradation rates.
    Ashley GW; Henise J; Reid R; Santi DV
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2318-23. PubMed ID: 23345437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.
    Schneider EL; Henise J; Reid R; Ashley GW; Santi DV
    Bioconjug Chem; 2016 May; 27(5):1210-5. PubMed ID: 26930186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology.
    Schneider EL; Ashley GW; Dillen L; Stoops B; Austin NE; Malcolm BA; Santi DV
    Eur J Pharm Biopharm; 2015 Jun; 93():254-9. PubMed ID: 25900863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation.
    Santi DV; Schneider EL; Ashley GW
    J Med Chem; 2014 Mar; 57(6):2303-14. PubMed ID: 24494988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Eliminative releasable linkers adapted for bioconjugation of macromolecules to phenols.
    Schneider EL; Robinson L; Reid R; Ashley GW; Santi DV
    Bioconjug Chem; 2013 Dec; 24(12):1990-7. PubMed ID: 24171387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
    Fontaine SD; Hann B; Reid R; Ashley GW; Santi DV
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):729-738. PubMed ID: 31321449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiolytically cleavable dithiobenzyl urethane-linked polymer-protein conjugates as macromolecular prodrugs: reversible PEGylation of proteins.
    Zalipsky S; Mullah N; Engbers C; Hutchins MU; Kiwan R
    Bioconjug Chem; 2007; 18(6):1869-78. PubMed ID: 17935288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
    Kim TH; Park CW; Kim HY; Chi MH; Lee SK; Song YM; Jiang HH; Lim SM; Youn YS; Lee KC
    Biol Pharm Bull; 2012; 35(7):1076-83. PubMed ID: 22791155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
    Irwin N; Patterson S; de Kort M; Moffett RC; Wisse JA; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    ChemMedChem; 2015 Aug; 10(8):1424-34. PubMed ID: 26059252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.
    Tully M; Wedepohl S; Kutifa D; Weise C; Licha K; Schirner M; Haag R
    Eur J Pharm Biopharm; 2021 Jul; 164():105-113. PubMed ID: 33957224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.
    Levy OE; Jodka CM; Ren SS; Mamedova L; Sharma A; Samant M; D'Souza LJ; Soares CJ; Yuskin DR; Jin LJ; Parkes DG; Tatarkiewicz K; Ghosh SS
    PLoS One; 2014; 9(2):e87704. PubMed ID: 24503632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.
    Gong N; Ma AN; Zhang LJ; Luo XS; Zhang YH; Xu M; Wang YX
    Br J Pharmacol; 2011 May; 163(2):399-412. PubMed ID: 21244372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated prodrugs of antidiabetic peptides amylin and GLP-1.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2018 Dec; 292():58-66. PubMed ID: 29729352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
    Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
    J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.
    Schneider EL; Hearn BR; Pfaff SJ; Reid R; Parkes DG; Vrang N; Ashley GW; Santi DV
    ACS Chem Biol; 2017 Aug; 12(8):2107-2116. PubMed ID: 28605180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Releasable PEGylation of proteins with customized linkers.
    Filpula D; Zhao H
    Adv Drug Deliv Rev; 2008 Jan; 60(1):29-49. PubMed ID: 17884239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Readily adaptable release kinetics of prodrugs using protease-dependent reversible PEGylation.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2016 May; 230():88-94. PubMed ID: 27067364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
    Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
    Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.